Management of Wilms' tumour

Current practice and future goals

John A Kalapurakal, Jeffrey S. Dome, Elizabeth J Perlman, Marcio Malogolowkin, Gerald M. Haase, Paul Grundy, Max J. Coppes*

*Corresponding author for this work

Research output: Contribution to journalReview article

131 Citations (Scopus)

Abstract

Most patients with Wilms' tumour in Europe and North America can be cured with treatment and subsequently lead a normal adulthood. However, for some, therapy as applied today results in long-term side-effects and creates a substantial burden on quality of life. Therefore, investigators involved in the management of patients with Wilms' tumour are increasingly focusing their efforts on curtailing the longterm sequelae of therapy. This aim has been achieved by lowering the total amount of chemotherapy, radiotherapy, or both administered to patients who have characteristics associated with favourable outcome. Although excellent survival has been maintained, many patients receive less therapy today than patients with similar characteristics did a decade or two ago. Better understanding of the biological processes that lead to this childhood cancer will allow further improvements in its management.

Original languageEnglish (US)
Pages (from-to)37-46
Number of pages10
JournalLancet Oncology
Volume5
Issue number1
DOIs
StatePublished - Jan 1 2004

Fingerprint

Wilms Tumor
Biological Phenomena
Therapeutics
North America
Radiotherapy
Quality of Life
Research Personnel
Drug Therapy
Survival
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Kalapurakal, John A ; Dome, Jeffrey S. ; Perlman, Elizabeth J ; Malogolowkin, Marcio ; Haase, Gerald M. ; Grundy, Paul ; Coppes, Max J. / Management of Wilms' tumour : Current practice and future goals. In: Lancet Oncology. 2004 ; Vol. 5, No. 1. pp. 37-46.
@article{61badf869ced47a8a95e7ac40cdc9f8c,
title = "Management of Wilms' tumour: Current practice and future goals",
abstract = "Most patients with Wilms' tumour in Europe and North America can be cured with treatment and subsequently lead a normal adulthood. However, for some, therapy as applied today results in long-term side-effects and creates a substantial burden on quality of life. Therefore, investigators involved in the management of patients with Wilms' tumour are increasingly focusing their efforts on curtailing the longterm sequelae of therapy. This aim has been achieved by lowering the total amount of chemotherapy, radiotherapy, or both administered to patients who have characteristics associated with favourable outcome. Although excellent survival has been maintained, many patients receive less therapy today than patients with similar characteristics did a decade or two ago. Better understanding of the biological processes that lead to this childhood cancer will allow further improvements in its management.",
author = "Kalapurakal, {John A} and Dome, {Jeffrey S.} and Perlman, {Elizabeth J} and Marcio Malogolowkin and Haase, {Gerald M.} and Paul Grundy and Coppes, {Max J.}",
year = "2004",
month = "1",
day = "1",
doi = "10.1016/S1470-2045(03)01322-6",
language = "English (US)",
volume = "5",
pages = "37--46",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "1",

}

Kalapurakal, JA, Dome, JS, Perlman, EJ, Malogolowkin, M, Haase, GM, Grundy, P & Coppes, MJ 2004, 'Management of Wilms' tumour: Current practice and future goals', Lancet Oncology, vol. 5, no. 1, pp. 37-46. https://doi.org/10.1016/S1470-2045(03)01322-6

Management of Wilms' tumour : Current practice and future goals. / Kalapurakal, John A; Dome, Jeffrey S.; Perlman, Elizabeth J; Malogolowkin, Marcio; Haase, Gerald M.; Grundy, Paul; Coppes, Max J.

In: Lancet Oncology, Vol. 5, No. 1, 01.01.2004, p. 37-46.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Management of Wilms' tumour

T2 - Current practice and future goals

AU - Kalapurakal, John A

AU - Dome, Jeffrey S.

AU - Perlman, Elizabeth J

AU - Malogolowkin, Marcio

AU - Haase, Gerald M.

AU - Grundy, Paul

AU - Coppes, Max J.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Most patients with Wilms' tumour in Europe and North America can be cured with treatment and subsequently lead a normal adulthood. However, for some, therapy as applied today results in long-term side-effects and creates a substantial burden on quality of life. Therefore, investigators involved in the management of patients with Wilms' tumour are increasingly focusing their efforts on curtailing the longterm sequelae of therapy. This aim has been achieved by lowering the total amount of chemotherapy, radiotherapy, or both administered to patients who have characteristics associated with favourable outcome. Although excellent survival has been maintained, many patients receive less therapy today than patients with similar characteristics did a decade or two ago. Better understanding of the biological processes that lead to this childhood cancer will allow further improvements in its management.

AB - Most patients with Wilms' tumour in Europe and North America can be cured with treatment and subsequently lead a normal adulthood. However, for some, therapy as applied today results in long-term side-effects and creates a substantial burden on quality of life. Therefore, investigators involved in the management of patients with Wilms' tumour are increasingly focusing their efforts on curtailing the longterm sequelae of therapy. This aim has been achieved by lowering the total amount of chemotherapy, radiotherapy, or both administered to patients who have characteristics associated with favourable outcome. Although excellent survival has been maintained, many patients receive less therapy today than patients with similar characteristics did a decade or two ago. Better understanding of the biological processes that lead to this childhood cancer will allow further improvements in its management.

UR - http://www.scopus.com/inward/record.url?scp=0347286871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347286871&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(03)01322-6

DO - 10.1016/S1470-2045(03)01322-6

M3 - Review article

VL - 5

SP - 37

EP - 46

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 1

ER -